Literature DB >> 23500346

Predictive value of the HAS-BLED score for the risk of recurrent intracranial hemorrhage after first spontaneous intracranial hemorrhage.

Koon-Ho Chan1, Gilberto Ka-Kit Leung2, Kui-Kai Lau1, Shasha Liu3, Wai-Man Lui2, Chu Pak Lau3, Hung-Fat Tse3, Jenny Kan-Suen Pu4, Chung-Wah Siu5.   

Abstract

BACKGROUND: Patients who survive intracranial hemorrhage (ICH) are at high risk of recurrence. The Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly (Age >65 years), Drugs/Alcohol Concomitantly (HAS-BLED) score has recently been developed to assess bleeding risk.
METHODS: This observational study was aimed to investigate the prognostic performance of the HAS-BLED score in predicting recurrent ICH. Consecutive patients (434) with a first spontaneous ICH who were not prescribed antiplatelet or anticoagulation therapy (59.8 ± 15.3 years; men, 62.3%) were recruited.
RESULTS: Most patients (71.6%) had a HAS-BLED score of >1. After a follow-up of 52.7 months, there were 42 ICH recurrences (2.25 per 100 patient-years). The risk of ICH recurrence increased with HAS-BLED score. Specifically, the risk of ICH recurrence with HAS-BLED score of 1, 2, 3, and 4 were 1.37, 2.38, 3.39, and 2.90 per 100 patient-years, respectively. The sensitivity and specificity of HAS-BLED was 79.1% and 29.2%, respectively, with C-statistic of 0.54 (0.50-0.59).
CONCLUSION: This study provided data on the risk of ICH recurrence stratified using the HAS-BLED score in patients after an ICH.
Copyright © 2014. Published by Elsevier Inc.

Entities:  

Keywords:  HAS-BLED score; Intracranial hemorrhage; Recurrence

Mesh:

Year:  2013        PMID: 23500346     DOI: 10.1016/j.wneu.2013.02.070

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  6 in total

1.  Efficacy and safety of dabigatran, rivaroxaban, and warfarin for stroke prevention in Chinese patients with atrial fibrillation: the Hong Kong Atrial Fibrillation Project.

Authors:  Wen-Hua Li; Duo Huang; Chern-En Chiang; Chu-Pak Lau; Hung-Fat Tse; Esther W Chan; Ian C K Wong; Gregory Y H Lip; Pak-Hei Chan; Chung-Wah Siu
Journal:  Clin Cardiol       Date:  2016-11-28       Impact factor: 2.882

Review 2.  Resumption of Anticoagulation After Intracranial Hemorrhage.

Authors:  Ivan Rocha Ferreira da Silva; Jennifer A Frontera
Journal:  Curr Treat Options Neurol       Date:  2017-09-30       Impact factor: 3.598

3.  Restarting antiplatelet therapy after spontaneous intracerebral hemorrhage: Functional outcomes.

Authors:  Ching-Jen Chen; Dale Ding; Thomas J Buell; Fernando D Testai; Sebastian Koch; Daniel Woo; Bradford B Worrall
Journal:  Neurology       Date:  2018-05-30       Impact factor: 9.910

4.  Impact of Antithrombotic Therapy in Atrial Fibrillation on the Presentation of Coronary Artery Disease.

Authors:  Pak Hei Chan; Wen Hua Li; Jo Jo Hai; Hung Fat Tse; Chung Wah Siu
Journal:  PLoS One       Date:  2015-06-22       Impact factor: 3.240

Review 5.  Anticoagulation Resumption After Intracerebral Hemorrhage.

Authors:  Yan-Guang Li; Gregory Y H Lip
Journal:  Curr Atheroscler Rep       Date:  2018-05-21       Impact factor: 5.113

6.  Empiric use of anticoagulation in hospitalized patients with COVID-19: a propensity score-matched study of risks and benefits.

Authors:  Bo Yu; Victor Perez Gutierrez; Alex Carlos; Gregory Hoge; Anjana Pillai; J Daniel Kelly; Vidya Menon
Journal:  Biomark Res       Date:  2021-05-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.